MINNEAPOLIS , Sept. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that one of its spatial biology brands, Lunaphore , is partnering with Discovery Life Sciences (Discovery) to add Lunaphore COMETTM , a best-in-class spatial biology platform, to Discovery's global suite of biospecimen products and specialty lab services supporting customers with clinical research. The strategic partnership leverages Lunaphore's COMET technology, the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities, with Discovery's scientific expertise to advance immuno-oncology, immunology, neuroscience, and infectious disease research across all development stages at a new level of precision and speed.
Discovery's Lunaphore COMET Hyperplex Immunofluorescence Services will facilitate the development of next-generation assays for clinical trials and provide multidimensional spatial biology insights to advance biomarker discovery, patient stratification, and translational medicine. "We are excited to expand our specialty lab services offering to include Lunaphore COMET Hyperplex Immunofluorescence Services," said Discovery CEO Greg Herrema . "By integrating COMET with Discovery's molecular pathology expertise, this partnership is poised to drive biomedical research breakthroughs.
This new service combined with our rigorous regulatory compliance processes will provide pharmaceutical companies with the ability to develop Clinic.
